Harbor Branch Oceanographic Institution And Novartis Pharma AG Sign AgreementFor Licensing And Development Of Anti-Cancer Compound, Discodermolide

April 16, 1998

FT. PIERCE, FL- Harbor Branch Oceanographic Institution, Inc., Fort Pierce, Florida, has entered into an agreement to license its marine-derived, anti-cancer agent, discodermolide, to Novartis Pharma AG, Basle, Switzerland, on an exclusive world-wide basis.

Discodermolide is an anti-cancer compound derived from the marine sponge, Discodermia dissoluta, first collected in 1987 by Dr. Shirley A. Pomponi, Director of Harbor Branch's Division of Biomedical Marine Research. The compound was isolated from the sponge and characterized by Dr. Sarath P. Gunasekera and Dr. Ross E. Longley at Harbor Branch in 1990. Subsequent studies by the Harbor Branch team and collaborators revealed the compound to be a potent, anti-tumor agent that is effective in killing human cancer cells in vitro with a mechanism of action similar to that of the clinical anti-cancer agent Taxol‰ .

Under terms of the license agreement, Harbor Branch grants Novartis exclusive, world-wide rights for the development, use, manufacture and sale of discodermolide for all potential therapeutic indications. Novartis will provide Harbor Branch with funding for continued research on discodermolide, as well as future payments based on developmental milestones and royalties from the sale of the compound as a drug for the treatment of cancer.

J. Seward Johnson, Jr., of Princeton, N.J., Chairman of Harbor Branch, states: "This agreement is the result of over 14 years of drug discovery research at Harbor Branch, and is the culmination of the last 8 years of research on discodermolide by the Harbor Branch team. Given the exciting and promising pre-clinical data on discodermolide and the expertise in drug development which Novartis provides, our hope is that discodermolide will eventually surpass other chemotherapeutic agents as an effective treatment for cancer".

Harbor Branch Oceanographic Institution, Inc. is one of the nation's premier not-for-profit oceanographic research and education facilities, dedicated to the exploration of the world's oceans, estuaries, and coastal regions for the benefit of all humankind.
-end-


Harbor Branch Oceanographic Institution

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.